Navigation Links
TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Date:12/5/2011

MALVERN, Pa., Dec. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead Smac mimetic drug candidate, TL32711, in elderly patients with acute myelogenous leukemia (AML). The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.

"In preclinical studies on primary human AML samples, TL32711 inhibits the growth and survival of AML cells as demonstrated in colony forming assays and a xenotransplantation model of the disease," said Martin Carroll, M.D., of the Hospital of the University of Pennsylvania. "These encouraging data along with TL32711's novel mechanism of action support its clinical development for AML where new treatment options are needed especially for the elderly."

"This clinical study represents another important step in advancing TL32711 as a potential treatment for AML and supports our goal of providing improved therapies for patients with cancer," said John Gill, TetraLogic's President and Chief Executive Officer.  "The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins (IAPs) represents a new broadly applicable approach to treat cancers that are normally resistant to therapies, including AML."

About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological mali
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... - Tamiflu Remains Fully Effective ... Latest surveillance data coming through ... virologists and clinicians indicates that,the influenza A(H3N2) virus is ... on the data published by ECDC Roche confirms that ...
... Conn., Jan. 19 SurgiQuest, Inc. is pleased to ... agreement with Intuitive Surgical, Inc. (Nasdaq: ISRG ... system using AirSeal(TM) technology for use with Intuitive,s laparoscopic ... invasive surgical procedures because it allows the surgeon to ...
... Corporation,s (Amex: ETC ) ("ETC" or ... of two BARA-MED(R) XD Monoplace Hyperbaric Chambers for ... St. Luke,s Hospital - Allentown Campus is part ... a nationally recognized, regional, integrated network of non-profit ...
Cached Biology Technology:Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 2Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 3Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 4SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology 2Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers 3Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers 4
(Date:7/9/2014)... with traumatic injuries have identified an immune marker ... a hospital-acquired infection. The study, led by clinician-scientists ... June in the journal Shock , is ... to the clinical implementation of quick-turnaround immune function ... system damage following critical illness or injury in ...
(Date:7/9/2014)... shark species may be able to cope with the rising ... , The Arctic today is best known for its tundra ... Roughly 53 to 38 million years ago during what is ... to a huge temperate forest with brackish water, home to ... creatures, crocodiles and giant tortoises. Much of what is known ...
(Date:7/9/2014)... U.S. may be on the verge of an economy driven ... cleaner than coal and is undergoing a production boom. It ... but recent research is casting serious doubts over just how ... & Engineering News (C&EN), the weekly news magazine of ... a senior correspondent at C&EN, explains that when burned as ...
Breaking Biology News(10 mins):Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... SLOVENIARidge and furrow rainwater-harvesting (RFRH) systems with mulches were ... northwest China to improve water availability and to increase ... rainwater harvesting zones, and bare or mulched furrows serve ... and are being promoted in many parts of the ...
... that can cope with sudden fluctuations in the weather could ... of plants. Scientists studying how tiny algae renew ... useful in developing crops suited to climates in which weather ... protein renewal takes place dictates how quickly they can adapt ...
... A manmade package filled with nature,s bone-building ingredients delivers ... bone injuries faster than products currently available, Cleveland researchers ... surgical elastic "implant device," essentially a wrapping that mimics ... growth factors and other natural components of the periosteum ...
Cached Biology News:Improved rainwater harvesting system promising 2It's all in the wrapping 2
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Acetyl CoA Carboxylase Antibody...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: